Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
MacroGenics
MGNX
MacroGenics
Immuno-oncology Setbacks And Cash Burn Will Block Progress Despite Promise
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.00
15.5% undervalued
intrinsic discount
16 Aug
US$1.69
Loading
1Y
-51.6%
7D
7.0%
Author's Valuation
US$2.0
15.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.0
15.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-219m
178m
2014
2017
2020
2023
2025
2026
2028
Revenue US$40.7m
Earnings US$6.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-3.66%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.50%
Calculation
US$6.62m
Earnings '28
x
23.84x
PE Ratio '28
=
US$157.76m
Market Cap '28
US$157.76m
Market Cap '28
/
64.39m
No. shares '28
=
US$2.45
Share Price '28
US$2.45
Share Price '28
Discounted to 2025 @ 7.22% p.a.
=
US$1.99
Fair Value '25
